Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis.
Saved in:
| Title: | Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis. |
|---|---|
| Authors: | Ku JH; Center for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu, Hawaii, USA.; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA., Qian L; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Sy LS; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Ackerson BK; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Rayens E; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Luo Y; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Qiu S; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Xu L; Medhealth Analytics Inc., Sugar Land, Texas, USA., Lee GS; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Modha PP; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Hoke CF; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.; Clinical Insights and Analytics, Atropos Health, NewYork, New York, USA., Joe C; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Amundsen BI; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Pirçon JY; GSK, Wavre, Belgium., Harrington L; GSK, Wavre, Belgium., Lecrenier N; GSK, Wavre, Belgium., Singer D; GSK, Philadelphia, Pennsylvania, USA., La EM; GSK, Philadelphia, Pennsylvania, USA., Allmon AG; GSK, Durham, North Carolina, USA., Luyts D; GSK, Wavre, Belgium., Tseng HF; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA. |
| Source: | Open forum infectious diseases [Open Forum Infect Dis] 2026 May 05; Vol. 13 (5), pp. ofag279. Date of Electronic Publication: 2026 May 05 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
